First Round of Abstract Submission Ends: Aug 30, 2025
Extended Early Bird Ends: Dec 30, 2024
Plenary Speakers
Prof. Reinhard Neubert
Martin Luther University Halle-Wittenberg, Germany
Title: Perspectives of nano-sized carrier systems in dermal delivery
Will update
Prof. Vladimir Muzykantov
University of Pennsylvania, USA
Title: Vascular nanomedicine delivery: fortuitous homing vs cognizant targeting.
Vladimir Muzykantov (MD in Internal Medicine from First Moscow Medical School, 1980 and Ph.D. in Biochemistry from Russian National Cardiology Research Center, 1985), joined PENN in 1993, got tenure in 2003 and in 2010 became a Full Professor and Vice-Chair of the Department of Systems Pharmacology and Translational Therapeutics. In 2010 he established Center for Targeted Therapeutics and Translational Nanomedicine (CT3N) at PENN, which he directs. For four decades he works on targeted delivery of pharmacological agents in the cardiovascular system. His research focuses on drug delivery by RBCs and endothelial targeting for treatment inflammation, thrombosis and ischemia. He published ~300 papers (h-index 82) and edited a book “Biomedical Aspects of Drug Targeting” (Kluwer, 2003). Honors include: AHA Established Investigator (1996), AHA Bugher Stroke Award (2000), Chair of Transatlantic Airway Conference on Targeting Molecular Signatures in Lungs (Luzerne, 2009), Gordon Conference on Drug Carriers (2012) and HLBI Division of Lung Diseases Workshop “Precision Therapeutics Delivery for Lung Diseases” (2014), Keynote Speaker in many forums. In 2022 he was elected as a Fellow of the International Society of Controlled Drug Release and in 2023 become the inaugural endowed PENN Founders Professor of Nanoparticle Research.
Prof. Howard R. Morris
And BioPharmaSpec Group
Title: 30 Years of Biomedical and Pharmaceutical Discovery and Characterisation with Q-TOF Mass Spectrometry
Professor Howard R. Morris FRS is the Emeritus Professor of Biological Chemistry at Imperial College, London. He is a Fellow of the Royal Society. He has over 400 peer reviewed publications and a citation index >40,000. He is the recipient of academic awards from several institutions including the Gold Medal Awardee of the University of Naples (1989), the European Blaise Pascale Medal for Life Sciences (2010), the Institute of Physics Franklin Medal and Prize (2012), the Royal Society Royal Medal and Prize (Queen’s Medal) for Interdisciplinary Sciences (2014), together with several Honorary Doctor of Science awards including the highest award of the Imperial College Council: Degree of Doctor of Science DSc honoris causa “In recognition of outstanding contributions made in the field of Biotechnology” (2021). Professor Morris is also the Chairman and Chief Scientific Officer of the BioPharmaSpec Group, a Contract Research Organisation supporting the Pharmaceutical and Biotechnology Industries in product development worldwide.
Prof. Thomas J. Webster
USA
Title: Eliminating Implant Infections without Pharmaceutical Agents: 30,000 Cases in Humans and Still Counting
Thomas J. Webster’s (H index: 129) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995; USA) and in biomedical engineering from RPI (Ph.D., 2000; USA). He has formed over a dozen companies who have numerous FDA approved medical products currently improving human health in over 30,000 patients. His technology is also being used in commercial products to improve sustainability and renewable energy. He is currently helping those companies and serves as a professor at Brown University, Saveetha University, Hebei University of Technology, UFPI, and others. Dr. Webster has numerous awards including: 2020, World Top 2% Scientist by Citations (PLOS); 2020, SCOPUS Highly Cited Research (Top 1% Materials Science and Mixed Fields); 2021, Clarivate Top 0.1% Most Influential Researchers (Pharmacology and Toxicology); 2022, Best Materials Science Scientist by Citations (Research.com); and is a fellow of over 8 societies. Prof. Webster is a former President of the U.S. Society for Biomaterials and has over 1,350 publications to his credit with over 55,000 citations. He was recently nominated for the Nobel Prize in Chemistry. Prof. Webster also recently formed a fund to support Nigerian student research opportunities in the U.S.
Prof. Yuji Matsuzawa
Sumitomo Hospital, Japan
Title: Adiponectin and atherosclerosis.
He graduated from Osaka university Medical School in 1966 and joined a research group of Lipid Research Laboratory at Osaka University in 1969.
He became Professor of the second Department of Internal Medicine of Osaka University in 1991 until 2003 when he moved to Sumitomo Hospital as Director and Emeritus Professor of Osaka University.
He has long worked on hyperlipidemia and obesity. He has discovered several novel disease entities such as "Autoimmune hyperchylomicrolemia" and "HyperHDLcholesterolemia caused by CETP deficiency" He was also interested in body fat distribution with respect to morbidity. He developed the method for fat analysis using CT scan and established the concept named visceral fat syndrome in which cardiovascular risks cluster by visceral fat accumulation. He also investigated biological characteristics of adipose tissue and found that adipose tissue abundantly expressed bioactive substances. (Gene 190:227, 1997, Nature Med 2: 800, 1996). During these works, he discovered "adiponectin" which may be one of key players in the mechanism of obesity-related diseases.
He is past President of International Atherosclerosis Society.
Prof. Zhiling Yu
Hong Kong Baptist University, China
Title: Concurrently Targeting TLR4 and EGFR Produces Potent Pharmacological Effects in Cancer Models.
Dr. Zhiling Yu holds a BSc degree in traditional Chinese medicine and a PhD degree in biochemistry. Dr. Yu is known for his research in herbal pharmacology, focusing on anti-atopic dermatitis, anti-nephritis, anti-rheumatic, and anticancer herbs. His research involves the identification of disease pathogenesis and druggable targets. He is also interested in the processing of Chinese medicinal materials.
Prof. Amirhossein Sahebkar
Mashhad University of Medical Sciences, Iran
Title: Lipoprotein(a) and Cardiovascular Risk: Advances in Measurement and Treatment
Amirhossein Sahebkar (Pharm.D., Ph.D., FESC) is a Professor at the Department of Biotechnology and the Biotechnology Research Center of Mashhad University of Medical Sciences (Mashhad, Iran). He also holds adjunct titles at Saveetha University (India) and the University of Western Australia (Australia). His research primarily focuses on novel therapeutic strategies for cardiometabolic diseases, encompassing both basic and clinical studies. Dr. Sahebkar is the national lead investigator for the European Atherosclerosis Society FHSC committee in Iran, a global initiative aimed at identifying and improving the care of patients with familial hypercholesterolemia. Dr. Sahebkar has received numerous research and scientific awards, including being named the most outstanding researcher of the decade in Iran by the Iran Academy of Medical Sciences. He serves on the editorial board of numerous national and international scientific journals. Clarivate Analytics ranked him among the top 1% of cited researchers worldwide in seven distinct scientific fields. He has published over 2,000 articles in peer-reviewed biomedical journals, garnering over 150,000 citations, according to Scopus statistics.
